Xencor (XNCR) Minority Interest (2023 - 2024)
Xencor (XNCR) posted quarterly Minority Interest of -$3.6 million for Q4 2024, down 1163.8% year-over-year from $337000.0 in Q1 2024, and down 22.02% quarter-over-quarter from -$2.9 million in Q3 2024.
Xencor (XNCR) Minority Interest (2023 - 2024) Analysis & Trends
Xencor (XNCR) has reported Minority Interest for 2 consecutive years, with -$3.6 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Minority Interest fell 1163.8% year-over-year to -$3.6 million; the TTM figure through Dec 2024 stood at -$3.6 million (down 1163.8% YoY), while the FY2024 annual figure was -$3.6 million, down 1163.8% from the prior year.
- Minority Interest fell to -$3.6 million in Q4 2024 per XNCR's latest filing, from -$2.9 million in the prior quarter.
- Across five years, Minority Interest topped out at $337000.0 in Q4 2023 and bottomed at -$3.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Xencor | 1.73 Bn | 1.36 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -3.59 Mn |
| Sep 30, 2024 | -2.94 Mn |
| Jun 30, 2024 | -1.78 Mn |
| Mar 31, 2024 | -339,000.00 |
| Dec 31, 2023 | 337,000.00 |